Thalia Therapeutics

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Media

AIM Rule 26

Regulatory news

Home

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

N4 Pharma's novel delivery systems advance towards commercialisation.pdf

Our latest news release for trade media highlights our pre-clinical siRNA delivery systems Nuvec® and LipTide®.

LipTide® is a lipid and peptide-based delivery system developed by Nanogenics and is currently being used in the formulation of a novel siRNA product, ECP105, which is targeting an unmet clinical need in the ophthalmology market for glaucoma patients.

N4 Pharma continues to show positive results in its pre-clinical research programme into Nuvec®, especially in the key areas of siRNA and oral delivery.

We were pleased to share our latest updates with the pharmaceutical and biopharmaceutical trade press and some key publications in this field have published it:

N4 Pharma’s novel delivery systems, Nuvec® and LipTide®, advance towards commercialisation